Clinical Trials
12 trialsNCT03244956 2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT05668962 2024-12-12
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Massachusetts General Hospital
Phase 2 Recruiting
NCT06405217 2024-05-08
Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment
Nanjing First Hospital, Nanjing Medical University
Phase NA Recruiting
NCT04971473 2024-03-28
Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Completed
NCT04137185 2024-03-06
Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Completed
NCT00415233 2023-12-19
HiLo
University College, London
Phase 3 Unknown
NCT04447183 2023-10-23
DTC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Unknown
NCT04964284 2023-10-23
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Unknown
NCT01837745 2023-05-17
ESTIMABL2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Active not recruiting
NCT00085293 2018-11-29
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
National Cancer Institute (NCI)
Phase 2 Completed
NCT00295763 2015-03-18
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
Sanofi
Phase 3 Completed